Boundless Bio Inc
BOLD1.200USD
+0.040+3.45%
Market hours （ET）Quotes delayed by 15 min
26.76MMarket Cap
LossP/E TTM
More Details of Boundless Bio Inc Company
Boundless Bio, Inc. is a clinical-stage oncology company, which is engaged in cancer therapeutics that addresses the unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA). Using its proprietary Spyglass platform, it identifies targets essential for ecDNA functionality in oncogene amplified cancer cells, then designs and develops small molecule drugs called ecDNA-directed therapeutic candidates (ecDTx) to inhibit those targets. Its lead ecDTx, BBI-355, is an oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells. BBI-355 demonstrated CHK1 inhibition and tumor regressions in ecDNA-enabled preclinical cancer models and is being studied in a first-in-human, Phase I/II clinical trial in patients with oncogene amplified cancers. Its second ecDTx, BBI-825, is an oral, selective inhibitor of ribonucleotide reductase, which is essential for ecDNA assembly and repair in cancer cells.
Company Info
Ticker SymbolBOLD
Company nameBoundless Bio Inc
IPO dateMar 28, 2024
CEOMr. Zachary D. Hornby
Number of employees64
Security typeOrdinary Share
Fiscal year-endMar 28
Address10955 Alexandria Way
CitySAN DIEGO
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code92121
Phone18587669912
Websitehttps://boundlessbio.com/
Ticker SymbolBOLD
IPO dateMar 28, 2024
CEOMr. Zachary D. Hornby
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Jonathan E. Lim, M.D.
Dr. Jonathan E. Lim, M.D.
Chairman of the Board
Chairman of the Board
653.48K
--
Mr. Zachary D. Hornby
Mr. Zachary D. Hornby
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Fabio Pucci, Ph.D.
Dr. Fabio Pucci, Ph.D.
Director
Director
--
--
Dr. Christian (Chris) Hassig, Ph.D.
Dr. Christian (Chris) Hassig, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Ms. Kristina M. Burow
Ms. Kristina M. Burow
Independent Director
Independent Director
--
--
Mr. David Hinkle
Mr. David Hinkle
Principal Financial Officer, Principal Accounting Officer, Treasurer
Principal Financial Officer, Principal Accounting Officer, Treasurer
--
--
Dr. James G. (Jamie) Christensen, Ph.D.
Dr. James G. (Jamie) Christensen, Ph.D.
Independent Director
Independent Director
--
--
Mr. Robert (Bob) Doebele
Mr. Robert (Bob) Doebele
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Jakob Loven, Ph.D.
Dr. Jakob Loven, Ph.D.
Director
Director
--
--
Dr. Nancy C. Whiting, Pharm.D.
Dr. Nancy C. Whiting, Pharm.D.
Director
Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Jonathan E. Lim, M.D.
Dr. Jonathan E. Lim, M.D.
Chairman of the Board
Chairman of the Board
653.48K
--
Mr. Zachary D. Hornby
Mr. Zachary D. Hornby
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Fabio Pucci, Ph.D.
Dr. Fabio Pucci, Ph.D.
Director
Director
--
--
Dr. Christian (Chris) Hassig, Ph.D.
Dr. Christian (Chris) Hassig, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Ms. Kristina M. Burow
Ms. Kristina M. Burow
Independent Director
Independent Director
--
--
Mr. David Hinkle
Mr. David Hinkle
Principal Financial Officer, Principal Accounting Officer, Treasurer
Principal Financial Officer, Principal Accounting Officer, Treasurer
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Wed, May 14
Updated: Wed, May 14
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
14.08%
ARCH Venture Partners
12.03%
RA Capital Management, LP
9.74%
Bayer HealthCare LLC
7.22%
Nextech Invest, Ltd.
5.49%
Other
51.44%
Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
14.08%
ARCH Venture Partners
12.03%
RA Capital Management, LP
9.74%
Bayer HealthCare LLC
7.22%
Nextech Invest, Ltd.
5.49%
Other
51.44%
Shareholder Types
Shareholders
Proportion
Investment Advisor
27.63%
Venture Capital
21.89%
Investment Advisor/Hedge Fund
11.86%
Hedge Fund
8.31%
Corporation
7.22%
Individual Investor
4.18%
Research Firm
0.51%
Pension Fund
0.10%
Bank and Trust
0.08%
Other
18.22%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
128
18.31M
81.78%
-1.81M
2025Q1
129
19.49M
87.25%
+660.31K
2024Q4
119
19.41M
87.06%
+540.27K
2024Q3
106
19.47M
87.42%
+538.85K
2024Q2
87
20.07M
90.11%
+1.04M
2024Q1
53
20.35M
91.48%
+20.35M
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Fidelity Management & Research Company LLC
3.15M
14.08%
-187.23K
-5.61%
Mar 31, 2025
ARCH Venture Partners
2.69M
12.03%
--
--
Apr 25, 2025
RA Capital Management, LP
2.18M
9.74%
--
--
Mar 31, 2025
Bayer HealthCare LLC
1.62M
7.22%
--
--
Apr 25, 2025
Nextech Invest, Ltd.
1.23M
5.49%
--
--
Mar 31, 2025
Citadel Advisors LLC
830.94K
3.71%
+40.30K
+5.10%
Mar 31, 2025
Redmile Group, LLC
725.20K
3.24%
-15.00K
-2.03%
Mar 31, 2025
Sectoral Asset Management Inc.
678.57K
3.03%
--
--
Mar 31, 2025
Lim (Jonathan E)
653.48K
2.92%
--
--
Apr 25, 2025
BlackRock Institutional Trust Company, N.A.
587.40K
2.62%
-9.12K
-1.53%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
Global X Russell 2000 ETF
0%
Proshares Ultra Russell 2000
0%
iShares Russell 2000 ETF
0%
iShares Russell 2000 Value ETF
0%
iShares Micro-Cap ETF
0%
ProShares UltraPro Russell2000
0%
ProShares Hedge Replication ETF
0%
iShares Russell 2000 Growth ETF
0%
Global X Russell 2000 ETF
Proportion0%
Proshares Ultra Russell 2000
Proportion0%
iShares Russell 2000 ETF
Proportion0%
iShares Russell 2000 Value ETF
Proportion0%
iShares Micro-Cap ETF
Proportion0%
ProShares UltraPro Russell2000
Proportion0%
ProShares Hedge Replication ETF
Proportion0%
iShares Russell 2000 Growth ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
